Human Longevity key facts
- Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health.
- Human Longevity’s last known valuation is $250.0M.
- It has raised $1.1B across 3 recorded rounds; the latest was Early Stage VC ($32.0M) in Mar 2023.
- Notable investors include CONNECT(San Diego), Amino Capital, OS Fund, NKM Capital, Panacea Venture — 36 tracked in total.
- Human Longevity has filed 4 Form Ds with the SEC since 2019, most recently Aug 2024 ($32.0M sold to 18 investors).
- Status: Privately Held (backing).
Who backs Human Longevity
36+Membership and data by Private Market View
- ·The complete investor list: 36 names
- ·Watch Human Longevity: the Monday email on marks, rounds and moves
Human Longevity funding rounds
3 roundsHuman Longevity valuation
Human Longevity's last known valuation is $250 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Human Longevity raised?
Human Longevity has raised $1.1 billion in total; 3 of its rounds are on record, from 2019 on. The largest on record was a $6.9 million early-stage round in Sep 2021; the most recent was a $32 million early-stage round in Mar 2023.
Human Longevity has filed 4 Form Ds with the SEC since 2019, most recently in Aug 2024 ($32 million sold to 18 investors).
Human Longevity investors
36 investors are on record for Human Longevity, including CONNECT(San Diego), Amino Capital, OS Fund and NKM Capital. The early-stage round in Mar 2023 drew 18 investors.
Who runs Human Longevity
1 person is listed on the Human Longevity team: 1 board member. 1 of them have a verified direct contact on file.
About Human Longevity
Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health. The company's platform addresses the age-related decline in endogenous stem cell function and concentrates on cancer, diabetes, obesity, heart and liver diseases, and dementia by combining deoxyribonucleic acid sequencing and expert analysis with machine learning, enabling people to shape their health and shift the practice of medicine from reactive to proactive technologies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 81
- Website
- humanlongevity.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Human Longevity’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.